Signum Technologies, a deep-tech company focused on applying artificial intelligence and computer vision to health security and healthcare monitoring solutions, has recently advanced its early-stage funding profile with new backing aimed at supporting its mission-driven technology development. The company develops imaging-based systems designed to detect environmental and physiological health risks, with applications spanning remote patient monitoring, contagion prediction, and frontline safety systems.

Founded in 2022, Signum Technologies operates at the intersection of national security innovation and healthcare technology commercialization. The company collaborates with U.S. government-linked innovation programs and research ecosystems to transition advanced biosensor and computational imaging technologies into deployable commercial solutions. Its platform includes contactless vital sign monitoring systems and AI-powered health assessment tools intended to reduce risk for healthcare workers and improve early detection capabilities in clinical and field environments.

The company has raised a total of approximately $1.2 million across its funding history, reflecting its early-stage positioning and focus on product development rather than large-scale commercialization. Its most recent financing event occurred in March 2026, when Signum Technologies secured a $1.2 million unattributed funding round to further advance its AI-driven imaging and health security technologies and expand its operational capabilities in both public and private sector markets.

Signum Technologies has attracted support from a small but strategically aligned group of institutional and accelerator investors. One of its key early backers is the Veteran Entrepreneur Investment Program, which participated in the company’s incubator-stage funding. The program focuses on supporting veteran-led and mission-driven startups, particularly those with potential applications in national security and advanced technology commercialization.

Another participant in the company’s funding ecosystem is the Northrop Grumman Technology Accelerator, which has supported Signum Technologies through accelerator programming aimed at fostering innovation in defense-adjacent technologies. Its involvement reflects growing industry interest in AI-enabled sensing systems that can be applied to both defense and healthcare use cases.

The I2A Accelerator Program also contributed to Signum Technologies’ early-stage development through incubation support. The accelerator focuses on helping early companies refine dual-use technologies, particularly those bridging commercial and government applications in areas such as healthcare, security, and advanced analytics.

Together, these investors reflect Signum Technologies’ positioning as a dual-use deep-tech startup operating at the convergence of healthcare innovation and national security applications. Rather than pursuing rapid scaling through large venture capital rounds, the company has instead followed a more incremental funding path supported by accelerator programs and strategic institutional partners that provide both capital and domain expertise.

The company’s leadership team, which includes CEO Sean Freitag, COO Andrew Gehman, and CTO Mark Farmer, has emphasized a long-term vision of building scalable AI-driven health security infrastructure. Their background in defense, cybersecurity, and enterprise software development has helped shape the company’s focus on robust, mission-oriented systems capable of operating in high-stakes environments.

As demand for remote healthcare monitoring and AI-assisted diagnostic tools continues to grow, Signum Technologies is positioning itself to expand its footprint across both public health and government sectors. Its funding base, while modest in size, reflects a strategic alignment with organizations focused on emerging technologies that support critical infrastructure resilience and advanced healthcare delivery systems.

Related Articles